Table 1 Patient demographics and baseline characteristics for patients with T1N0 hormone receptor–positive breast cancer from the Stockholm randomized trial and multi-institutional cohorts
Stockholm randomized trial cohort (N = 237) | Multi-institutional cohort (N = 210) | |
|---|---|---|
Age at surgery, y | ||
<50 | 2 (1%) | 66 (31%) |
50–59 | 68 (29%) | 66 (31%) |
60–69 | 156 (66%) | 59 (28%) |
≥70 | 11 (5%) | 19 (9%) |
Tumor size | ||
T1mi | 0 (0%) | 2 (1%) |
T1a | 7 (3%) | 13 (6%) |
T1b | 76 (32%) | 67 (32%) |
T1c | 154 (65%) | 128 (61%) |
Tumor grade | ||
Well | 54 (23%) | 63 (30%) |
Moderate | 158 (67%) | 126 (60%) |
Poor | 25 (11%) | 21 (10%) |
PR status | ||
Negative | 54 (23%) | NA |
Positive | 164 (69%) | NA |
Unknown | 19 (8%) | NA |
HER2 status | ||
Negative | 225 (95%) | 190 (90%) |
Positive | 12 (5%) | 20 (10%) |
Received adjuvant chemotherapy | ||
No | 237 (100%) | 167 (80%) |
Yes | 0 (0%) | 43 (20%) |
Distant recurrences | ||
Late (>5 y) | 16 (7%) | 9 (4%) |
BCI risk group | ||
Low | 160 (68%) | 135 (64%) |
High | 77 (32%) | 75 (36%) |
H/I category | ||
H/I Low | 160 (68%) | 123 (59%) |
H/I High | 77 (32%) | 87 (41%) |
